Accrol expects fiscal year 2022 revenues to rise 17% to £159.4M as its market share grows to 16.0% from 15.3% in H1, reflecting growth at discounter retailers; group navigated inflationary pressures through price increases, further process efficiencies

Sample article from our Tissue & Hygiene

May 17, 2022 (press release) –

FY22 in line with market expectations

 

Accrol (AIM: ACRL), the UK's leading independent tissue converter, announces the following trading update ahead of its Final Results for the year ended 30 April 2022 ("FY22" or the "Period"), which are scheduled to be released in September 2022.

 

In the period since the Company's last trading update of 12 January 2022, the Group has continued to demonstrate resilience against a challenging backdrop of rapid cost inflation. As a result, revenue, adjusted EBITDA, and adjusted profit before tax for FY22 are expected to be in line with market expectations1.

 

The Group has successfully navigated the substantial inflationary pressures on input costs, including pulp, energy, and supply chain, by engaging constructively with its customers to pass-on these additional costs, through significant price increases and further process efficiencies.

 

Highlights

 

FY22

Revenue, adjusted EBITDA, and adjusted profit before tax for FY22 in line with market expectations1

Successful recovery of all increased input costs secured by the end of Q4 FY22

Market share by revenue increased to 16.0% (H1 FY22: 15.3%) and by volume to 19.5% (H1 FY22: 18.9%)

New customers secured and deeper penetration of key accounts, through increasing product diversity - notably Amazon, Unitas (30k convenience stores) and Ocado

Final elements of the extensive automation programme and machine investment in the Tissue business completing in Q1 FY23. Only planned modest levels of maintenance investment capital required going forward

 

Outlook

Revenue for the year ending 30 April 20231 ("FY23") now expected to be in the range of £200m to £220m, as a result of the successful recovery of all input cost increases

The Group is well positioned to benefit from its product range and its supply positions across the discount retailers as their growth accelerates following the pandemic and the inflationary pressures now impacting consumers

Increasing Board confidence in FY23 outcome

 

1 For the purposes of this announcement, the Group believes market consensus for the year ended April 2022 to be revenue of £160m, adjusted EBITDA of £9m and adjusted PBT of £1m, and the for the year ended April 2023, revenue of £185m, adjusted EBITDA of £15m and adjusted PBT of £7m.

 

FY22 Financials

 

The overall UK tissue market has grown by 0.7% to £2.1bn2 based on retail sale value, reflecting the inflationary pressures within the market.  Accrol's market share growth has returned, increasing to 16.0%2 from 15.3%2 at H1 FY22 (FY21: 15.9%)2, reflecting the strong recovery of the discounter retailers in recent months. (2 Source: Kantar)

 

Total revenues in FY22 increased by 17% to £159.4m (FY21: £136.6m).  Market conditions continued to improve throughout the year with shopping behaviours becoming more normalised as COVID related restrictions were eased and then removed completely.

 

Net debt (pre-IFRS16) at 30 April 2022 was £27.5m, (31 October 2021: £21.6m), following the Group's accelerated investment in automation and the necessary expansion in working capital to manage supply constraints and rising costs. 

 

The Group recently amended and extended its existing banking arrangements, through to August 2024 providing additional facilities to support its growth. These new facilities provide increased headroom in both the scale, tenure and liquidity of the facilities and the associated banking covenants. The amended facilities provide an additional £8.5m of funding headroom, an increase of c.25% over and above the previous arrangements that would have expired in August 2023. Given the breadth and depth of the Group's historic automation and machine investment programme, any material future capital investment will be capacity and earnings enhancing.

 

Foreign exchange

 

The majority of the Group's tissue requirement is fulfilled through the purchase of parent reels in US dollars. Forward foreign currency contracts are used in the purchase process for this product. The nature of these contracts allows time for the Company to manage any significant and unforeseen movements in the exchange rate through pricing agreements with its customers.

 

Strategic review

 

The Strategic Review, announced on 12 January 2022, is ongoing and the Board intends to provide a full update in the FY22 results announcement in September.

 

Outlook

 

Whilst remaining mindful of the extremely challenging external environment, the Board views the prospects for Accrol with increasing confidence, given the strong recovery of input cost rises, strengthened customer relationships, improved levels of service and quality, and its higher value product range.

 

The Group expects volumes across the UK tissue sector to return to pre-pandemic levels and that its main market, the discount retailers, will grow strongly, as consumers seek value and quality, given tighter household budgets.

 

Gareth Jenkins, Chief Executive Officer of Accrol, said:

 

"This has been the most challenging period in the industry that I have experienced, with tissue pricing reaching unprecedented levels, driven by energy prices and supply constraints. We have successfully recovered these increased input costs to date and are confident we can continue to recover any further rises through innovation, efficiency and our supportive retailer customer base.

 

"We have a well invested business and exit the year in a strong position both operationally and commercially." 

 

Dan Wright, Executive Chairman of Accrol, added:

 

"The new improved banking arrangements demonstrate continued confidence in the Group's operating performance and ongoing support for our development plans. The investments we have already made into the efficiency of our operations have served us well through these incredibly challenging times and we are confident that they will bear considerable fruit in FY23 and beyond."

 

The Group has produced a short video to showcase its operations and investment in the extensive automation of the business. Click here: Accrol Today.

 

For further information, please contact:

 

 

 

Accrol Group Holdings plc

 

Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer

 

Richard Newman, Chief Financial Officer

 

 

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King

Tel: +44 (0) 203 829 5000

 

 

Liberum Capital Limited (Joint Broker)

Tel: +44 (0) 20 3100 2222

Clayton Bush / Edward Thomas

 

 

 

Belvedere Communications Limited

 

Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525

 

accrolpr@belvederepr.com

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisitions of LTC in Leicester and JD in Flint, North Wales, the Group now operates from six manufacturing sites, including four in Lancashire, which generate revenues totalling c.16% of the c£2.1bn UK retail tissue market.

 

For more information, please visit www.accrol.co.uk.

 

Link for Accrol Today video: https://www.accrol.co.uk/our-business/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.